Guiding-Directives

GUIDING DIRECTIVES

Navy Drug Screening Labs


DODI 1010.01, USD(P&R)	Military Personnel Drug Abuse Testing Program (MPDATP)	Issuance Date 13Sep12	Change 1 effective 14Feb18
DODI 1010.04, USD(P&R)	Problematic Substance Use by DOD Personnel	Issuance Date 20Feb14	Change 1 effective 06May20
DODI 1010.09, USD(P&R)	DOD Civilian Employee Drug-Free Workplace Program	Issuance Date 22Jun12	Change 1 effective 28Jun18
DODI 1010.16, USD(P&R)	Technical Procedures for the Military Personnel Drug Abuse Testing Program (MPDATP)	Issuance Date 15Jun20
OPNAVINST 5350.4E, CNO(MPT&E)	Navy Alcohol and Drug Abuse Prevention and Control	Issuance Date 28Mar22
MCO 5300.17A	Marine Corps, Marine Corps Substance Abuse Program	Issuance Date 25Jun18	Change 1 effective 23Feb23

Web Resources

Clinicians

Clinical guidance, including recognition, management and clinical isolation guidance are generally covered by CDC: CDC Clinical Overview

Clinical management for Fleet medical personnel can be found in the NMCFHPC Fleet Mpox Medical Guidance

Clinical guidance for MTFs can be found in the DHA Mpox Guidance Update_5Sept2024

Currently, neither mpox testing nor treatment are readily available in a forward deployed operational setting. Units should identify suspected cases, isolate them, and move them for care at an MTF when operationally feasible.

Bureau of Medicine and Surgery
7700 Arlington Blvd. Ste. 5113 Falls Church, VA 22042-5113
This is an official U.S. Navy website
This is a Department of Defense (DoD) Internet computer system.

General Navy Medical Inquiries (to Bureau of Medicine and Surgery): usn.ncr.bumedfchva.list.bumed---pao@health.mil